Stifel Nicolaus Reaffirms “Buy” Rating for Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a research note issued to investors on Wednesday, Marketbeat.com reports. They presently have a $45.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 79.14% from the stock’s previous close.

JANX has been the topic of a number of other research reports. Guggenheim assumed coverage on shares of Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target on the stock. Piper Sandler assumed coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, Raymond James Financial assumed coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They set an “outperform” rating and a $65.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $80.92.

Janux Therapeutics Stock Performance

Shares of JANX opened at $25.12 on Wednesday. The stock has a market cap of $1.51 billion, a PE ratio of -13.96 and a beta of 2.84. Janux Therapeutics has a fifty-two week low of $21.97 and a fifty-two week high of $71.71. The firm’s 50-day simple moving average is $24.59 and its two-hundred day simple moving average is $26.44.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). Equities research analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its holdings in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Janux Therapeutics by 230.0% in the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock worth $4,379,000 after purchasing an additional 132,121 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Janux Therapeutics by 64.8% in the second quarter. Lazard Asset Management LLC now owns 99,858 shares of the company’s stock worth $2,306,000 after purchasing an additional 39,278 shares during the last quarter. Finally, Engineers Gate Manager LP boosted its holdings in Janux Therapeutics by 115.0% in the second quarter. Engineers Gate Manager LP now owns 39,749 shares of the company’s stock worth $918,000 after purchasing an additional 21,258 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.